News

TipRanks on MSN14h

Akero Therapeutics’ efruxifermin shows efficacy in Phase 2b MASH, fibrosis trial

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...
The Manila Times14h

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...
The Bakersfield Californian14h

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

Akero Therapeutics: Why I'm Reversing My Contrarian Buy Rating To A Contrarian Sell Rating

I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...